PMID- 35936040
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220809
IS  - 1880-4276 (Print)
IS  - 1883-2148 (Electronic)
IS  - 1880-4276 (Linking)
VI  - 38
IP  - 4
DP  - 2022 Aug
TI  - Design of Mid-Q Response: A prospective, randomized trial of adaptive cardiac 
      resynchronization therapy in Asian patients.
PG  - 608-614
LID - 10.1002/joa3.12731 [doi]
AB  - AIMS: The aim of the Mid-Q Response study is to test the hypothesis that adaptive 
      preferential left ventricular-only pacing with the AdaptivCRT algorithm has 
      superior clinical outcomes compared to conventional cardiac resynchronization 
      therapy (CRT) in heart failure (HF) patients with moderately wide QRS duration 
      (>/=120 ms and <150 ms), left bundle branch block (LBBB), and normal 
      atrioventricular (AV) conduction (PR interval </=200 ms). METHODS: This 
      prospective, multi-center, randomized, controlled, clinical study is being 
      conducted at approximately 60 centers in Asia. Following enrollment and baseline 
      assessment, eligible patients are implanted with a CRT system equipped with the 
      AdaptivCRT algorithm and are randomly assigned in a 1:1 ratio to have AdaptivCRT 
      ON (Adaptive Bi-V and LV pacing) or AdaptivCRT OFF (Nonadaptive CRT). A minimum 
      of 220 randomized patients are required for analysis of the primary endpoint, 
      clinical composite score (CCS) at 6 months post-implant. The secondary and 
      ancillary endpoints are all-cause and cardiovascular death, hospitalizations for 
      worsening HF, New York Heart Association (NYHA) class, Kansas City Cardiomyopathy 
      Questionnaire (KCCQ), atrial fibrillation (AF), and cardiovascular adverse events 
      at 6 or 12 months. CONCLUSION: The Mid-Q Response study is expected to provide 
      additional evidence on the incremental benefit of the AdaptivCRT algorithm among 
      Asian HF patients with normal AV conduction, moderately wide QRS, and LBBB 
      undergoing CRT implant.
CI  - (c) 2022 The Authors. Journal of Arrhythmia published by John Wiley & Sons 
      Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
FAU - Kusano, Kengo
AU  - Kusano K
AUID- ORCID: 0000-0002-5760-9285
AD  - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center 
      Osaka Japan.
FAU - Park, Seung-Jung
AU  - Park SJ
AD  - Sungkyunkwan University School of Medicine Samsung Medical Center Seoul South 
      Korea.
FAU - Johar, Sofian
AU  - Johar S
AD  - Gleneagles Jerudong Park Medical Centre and Institute of Health Sciences 
      Universiti Brunei Darussalam Bandar Seri Begawan Brunei Darussalam.
FAU - Lim, Toon Wei
AU  - Lim TW
AD  - National University Hospital Singapore Singapore.
FAU - Gerritse, Bart
AU  - Gerritse B
AD  - Medtronic Bakken Research Center Maastricht The Netherlands.
FAU - Hidaka, Kazuhiro
AU  - Hidaka K
AUID- ORCID: 0000-0003-1254-7647
AD  - Medtronic Japan Tokyo Japan.
FAU - Aonuma, Kazutaka
AU  - Aonuma K
AD  - Department of Cardiology, Faculty of Medicine University of Tsukuba Tsukuba 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20220520
PL  - Japan
TA  - J Arrhythm
JT  - Journal of arrhythmia
JID - 101263026
PMC - PMC9347206
OTO - NOTNLM
OT  - adaptive CRT
OT  - atrioventricular conduction
OT  - cardiac resynchronization therapy
OT  - clinical outcome
OT  - left bundle branch block
OT  - left ventricular pacing
COIS- Kengo Kusano, MD, PhD: Speaker honoraria from Daiichi Sankyo Company, Ltd., 
      Japan, Bristol-Myers Squibb, Biotronik Japan, and Medronic Japan, and research 
      grants from Medtronic Japan. Seung-Jung Park, MD, PhD: Research grants and 
      speaker honoraria from Boston Scientific Korea, Abbott Korea, Biotronik Korea, 
      and Medtronic Korea. Sofian Johar, MB, BChir, PhD: speaker for Medtronic and 
      Johnson and Johnson. Toon Wei Lim MD, PhD: Speaker for Biotronik, Medtronic, and 
      Abbott. Research support from Medtronic and Biotronik. Kazuhiro Hidaka: employee 
      and shareholder of Medtronic. Bart Gerritse: employee and shareholder of 
      Medtronic. Kazutaka Aonuma, MD, PhD: Speaker honoraria from Boehringer Ingelheim 
      GmbH, Medtronic Japan Co., Ltd., Daiichi Sankyo Co., Ltd., Japan, and Abbott 
      Medical Japan Co., Ltd., and research grants from Otsuka Pharmaceutical Co., Ltd, 
      ASTEC Co., Ltd, Astellas Pharma Inc., Johnson & Johnson, Takeda Pharmaceutical 
      Co., Ltd, TEIJIN PHARMA LIMITED, SHIONOGI & CO., LTD., Medical Corporation 
      Tsukuba Kinenkai, Abbott Medical Japan Co., Ltd., and belongs to endowed 
      departments by Boston Scientific Corporation, Japan Lifeline Co., Ltd., Nihon 
      Cohden Corporation, BIOTRONIK Japan Inc., Toray Industries, Inc., Boehringer 
      Ingelheim GmbH, Century Medical Inc.
EDAT- 2022/08/09 06:00
MHDA- 2022/08/09 06:01
PMCR- 2022/05/20
CRDT- 2022/08/08 03:43
PHST- 2022/01/19 00:00 [received]
PHST- 2022/04/28 00:00 [accepted]
PHST- 2022/08/08 03:43 [entrez]
PHST- 2022/08/09 06:00 [pubmed]
PHST- 2022/08/09 06:01 [medline]
PHST- 2022/05/20 00:00 [pmc-release]
AID - JOA312731 [pii]
AID - 10.1002/joa3.12731 [doi]
PST - epublish
SO  - J Arrhythm. 2022 May 20;38(4):608-614. doi: 10.1002/joa3.12731. eCollection 2022 
      Aug.